NTNhat Quang N. Thai

Nhat Quang N. Thai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nhat Quang N. Thai has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Jeffrey B. Schwimmer

    Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics University of California San Diego School of Medicine La Jolla California USA

    4 shared publications
  • Kimberly P. Newton

    Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA

    4 shared publications
  • Cynthia A. Behling

    Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA

    2 shared publications
  • Nidhi P. Goyal

    Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA

    2 shared publications
  • Aladdin H. Shadyab

    Herbert Wertheim School of Public Health and Human and Human Longevity Science, University of California San Diego, 9500 Gilman Drive #0725, La Jolla, CA, 92093, USA; Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California San Diego, 9500 Gilman Drive #0725, La Jolla, CA, 92093, USA

    1 shared publication
  • Alexander Ivan B. Posis

    Department of Public Health Sciences, School of Medicine, University of California, Davis

    1 shared publication

Latest Publications

  • Open Access

    Alcohol use trajectories and liver enzyme changes in adolescents with MASLD: A longitudinal multicenter cohort

    by Nhat Quang N. Thai, Laura A. Wilson, Cynthia A. Behling, Jeanne M. Clark, Jean P. Molleston, Kimberly P. Newton, Rany M. Salem, Gretchen Bandoli, John Alcaraz, Noe Crespo, et al.

    Objectives: To characterize longitudinal patterns of alcohol use and evaluate associations with liver enzyme changes in youth with metabolic dysfunction–associated steatotic liver disease (MASLD). Methods: We analyzed 1172 children with biopsy-confirmed MASLD and longitudinal Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) data. Group-based trajectory modeling identified alcohol use patterns over time. Linear mixed models assessed associations between alcohol trajectory groups and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT). Generalized linear mixed models evaluated predictors of alcohol use, including age, sex, body mass index (BMI), fibrosis stage, and household income. Results: Among participants diagnosed with MASLD in childhood, 206 (17.6%) reported alcohol use during adolescence or early adulthood. Three alcohol-use groups were identified: non-users, adolescent initiators, and adult initiators. Heavy episodic drinking was reported by 48 of 71 adolescent initiators (67.6%) and 53 of 135 adult initiators (39.3%). Compared with non-users, alcohol initiators had lower liver chemistry values at enrollment but greater annual increases during follow-up. Adolescent initiators had a 4% greater annual increase in ALT, while adult initiators had 6%, 4%, and 3% greater annual increases in ALT, AST, and GGT, respectively. Conclusions: Nearly 1 in 5 youth with MASLD reported alcohol use during adolescence or early adulthood despite ongoing subspecialty care. Alcohol-use trajectories were associated with greater annual increases in liver chemistries, particularly among participants with heavy episodic drinking. These findings support routine alcohol screening and developmentally tailored anticipatory guidance in pediatric MASLD care.

  • Open Access

    Neighborhood disparities and metabolic dysfunction–associated steatotic liver disease in children with overweight or obesity

    by Ananya Venkatesh, Nhat Thai, Patricia Ugalde-Nicalo, Martha R. Smith, Laura E. Bauman, Cynthia A. Behling, Kimberly P. Newton, Romeo C. Ignacio, Jeffrey B. Schwimmer

    Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common pediatric liver disease, yet known biological risk factors do not fully explain its development. This study evaluated the association between social determinants of health (SDH)—including income, education, housing, and environmental factors—and MASLD in children with overweight or obesity. Methods: This cross-sectional study included children with overweight or obesity evaluated in pediatric gastroenterology clinics, stratified by the presence of MASLD. Participants’ residential census tracts were linked to the California Healthy Places Index (HPI), where higher scores indicate greater socioeconomic advantage. Generalized linear regression models, adjusted for age, sex, race, ethnicity, and body mass index (BMI), assessed associations between SDH and MASLD. Results: The study included 888 children (mean age: 12.8±2.9 y, mean BMI: 30.6±6.4 kg/m 2 ). Children with MASLD lived in neighborhoods with significantly lower HPI scores than those without MASLD (−0.22 vs. −0.03; 41st vs. 49th percentile, p =0.01). They also resided in areas with significantly lower socioeconomic advantage across multiple HPI subdomains, including housing (−0.16 vs. 0.03; 44th vs. 51st percentile, p p <0.001) scores. Conclusions: Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than their peers with overweight or obesity but without MASLD. These findings highlight potential SDH targets for public health interventions aimed at reducing MASLD risk in children.


  • Top Cited Papers

    Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study

    by Jeffrey B. Schwimmer, Nhat Quang N. Thai, Sheila L. Noon, Patricia Ugalde-Nicalo, Sabina R. Anderson, Lauren F. Chun, Rhys S. David, Nidhi P. Goyal, Kimberly P. Newton, Eleanor G. Hansen, et al.

    Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export


  • The association of leukocyte telomere length with exceptional longevity among older women

    by Nhat Quang N. Thai, Andrea Z. LaCroix, Bernhard Haring, Jean Wactawski-Wende, JoAnn E. Manson, Alexander Ivan B. Posis, Aladdin H. Shadyab

    The association of leukocyte telomere length (LTL) with survival to late life with intact mobility has not been adequately studied. This prospective cohort study consisted of 1451 postmenopausal women from a Women’s Health Initiative ancillary study, who were eligible, because of birth year, to survive to age 90 as of March 6, 2021. LTL was measured by Southern blot at baseline (1993–1998). Associations between LTL and survival to age 90 were evaluated using logistic regression models adjusted for socio-demographic characteristics, health factors, and lifestyle factors. Multinominal logistic regression was utilized to examine associations of LTL with survival to age 90 with or without intact mobility. Mediation analysis examined the extent to which incident coronary heart disease and stroke-mediated the association between LTL and longevity. Overall, 76.7% of women were White, and 23.3% were Black; average age at baseline was 70.4±3.5 years. Relative to death before age 90, the odds of survival to age 90 were 60% higher (OR, 1.60; 95% CI, 1.28–2.01), the odds of survival to age 90 with mobility limitation were 72% higher (OR, 1.72; 95% CI, 1.33–2.21), and the odds of survival to age 90 with intact mobility were 44% higher (OR, 1.44; 95% CI, 1.06–1.95) for every one kilobase longer LTL. Absence of CHD, stroke, or CHD/stroke mediated the association of LTL with survival to age 90 by 11.1%, 37.4%, and 31.3%, respectively; however, these findings were not significant. Longer LTL was associated with higher odds of survival to age 90 among older women.